CGRP as the target of new migraine therapies — successful translation from bench to clinic

@article{Edvinsson2018CGRPAT,
  title={CGRP as the target of new migraine therapies — successful translation from bench to clinic},
  author={Lars Edvinsson and Kristian Agmund Haanes and Karin Warfvinge and Diana N. Krause},
  journal={Nature Reviews Neurology},
  year={2018},
  volume={14},
  pages={338-350}
}

• Lars Edvinsson, Kristian Agmund Haanes, +1 author Diana N. Krause
• Published in Nature Reviews Neurology 2018
• DOI:10.1038/s41582-018-0003-1

Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few… CONTINUE READING

View on Springer

Alternate Sources

Save to Library

Create Alert

Cite